Human induced pluripotent stem cells (iPSCs) have the potential to treat many diseases by autologous transplantation. However, before they can be used clinically, efficient and reproducible methods are required for their derivation and differentiation into therapeutic cell types. In the case of genetic diseases, methods for correcting disease-causing mutations also need to be developed. Here we will use this approach to design a treatment for thalassemia, which is caused by mutations in globin genes. This approach avoids the potential genotoxic complications of conventional gene therapy with retroviral vectors and should achieve consistent, regulated globin expression from the endogenous locus. We will derive IPSCs from the adult cells of patients with thalassemia using lentivirus and foamy virus vectors that express reprogramming transgenes. Some of the vectors will be designed for transient gene delivery to create transgene-free iPSCs. These IPSCs will be differentiated into hematopoietic cells to determine the best adult cell type and reprogramming vectors for creating iPSCs with hematopoietic potential. Adeno-associated virus gene targeting vectors will be used to correct the globin mutations in these thalassemic IPSCs, and globin expression will be studied after their differentiation into erythroid progeny. This research plan capitalizes on recent advances in the derivation of patient-specific stem cells, which in combination with gene correction constitutes a new paradigm for the treatment of genetic diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL053750-16
Application #
7799411
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2009-09-01
Project End
2014-08-31
Budget Start
2010-04-08
Budget End
2011-03-31
Support Year
16
Fiscal Year
2010
Total Cost
$450,893
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Constantinou, Varnavas C; Bouinta, Asimina; Karponi, Garyfalia et al. (2017) Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with ?-thalassemia major. Transfusion 57:1031-1039
Gori, Jennifer L; Butler, Jason M; Kunar, Balvir et al. (2017) Endothelial Cells Promote Expansion of Long-Term Engrafting Marrow Hematopoietic Stem and Progenitor Cells in Primates. Stem Cells Transl Med 6:864-876
Psatha, Nikoletta; Karponi, Garyfalia; Yannaki, Evangelia (2016) Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol 44:528-39
Li, Li B; Ma, Chao; Awong, Geneve et al. (2016) Silent IL2RG Gene Editing in Human Pluripotent Stem Cells. Mol Ther 24:582-91
Karponi, Garyfalia; Psatha, Nikoletta; Lederer, Carsten Werner et al. (2015) Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood 126:616-9
Vierstra, Jeff; Reik, Andreas; Chang, Kai-Hsin et al. (2015) Functional footprinting of regulatory DNA. Nat Methods 12:927-30
Liu, Mingdong; Maurano, Matthew T; Wang, Hao et al. (2015) Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol 33:198-203
Qi, Heyuan; Liu, Mingdong; Emery, David W et al. (2015) Functional validation of a constitutive autonomous silencer element. PLoS One 10:e0124588
Polak, Paz; Karli?, Rosa; Koren, Amnon et al. (2015) Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518:360-364
Watts, Korashon L; Beard, Brian C; Wood, Brent L et al. (2014) No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. Exp Hematol 42:497-504

Showing the most recent 10 out of 161 publications